<DOC>
	<DOCNO>NCT00239382</DOCNO>
	<brief_summary>The objective trial ass efficacy safety 15 mg meloxicam i.m . daily compare 15 mg meloxicam tablet daily p.o . patient Rheumatoid arthritis time period 7 day .</brief_summary>
	<brief_title>A Study Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This randomize ( 1:1 ) , open-label , multi-center , active-control , parallel-group study compare efficacy 15 mg meloxicam i.m . daily compare 15 mg meloxicam tablet daily p.o . patient rheumatoid arthritis time period 7 day . The primary endpoint : - Patient 's assessment overall pain - Patient 's global assessment disease activity The secondary endpoint : - Tender/swollen joint count - Investigator 's global assessment disease activity - Patient 's assessment physical function - Duration morning stiffness - Patient status regard change arthritic condition assess patient/investigator - Onset action - Time maximum pain relief - Paracetamol consumption - Withdrawals due inadequate efficacy - Final global assessment efficacy patient/inveatigator Safety endpoints - Local tolerability assessment injection patient/investigator - Patient 's /Investigator 's assessment overall tolerability - Number , nature severity adverse event - Laboratory investigation - Withdrawals due safety reason Patients eligible trial meet inclusion exclusion criterion give inform consent randomize one two treatment group ( i.e . meloxicam ampoule meloxicam tablet ) . The study period total 8-14 day include screening , randomisation , study drug administration , 7-day follow-up . The relevant assessment perform day randomisation 7-day follow . The primary endpoint : Pain active movement , The secondary endpoint : - Pain rest - Patient status regard change arthritic condition assess patient/investigator - Patient 's assessment arthritic condition - Onset action - Time maximum pain relief - Paracetamol consumption - Withdrawals due inadequate efficacy - Final global assessment efficacy patient/investigator Safety endpoints - Local tolerability assessment injection patient/investigator - Patient 's /Investigator 's assessment overall tolerability - Number , nature severity adverse event - Laboratory investigation - Withdrawals due safety reason Patients eligible trial meet inclusion exclusion criterion give inform consent randomize one two treatment group ( i.e . meloxicam ampoule meloxicam tablet ) . The study period total 8-14 day include screening , randomisation , study drug administration , 7-day follow-up . The relevant assessment perform day randomisation 7-day follow . Study Hypothesis : The null hypothesis interest primary endpoint meloxicam ampoule inferior oral meloxicam . The alternative meloxicam ampoule noninferior oral meloxicam . Comparison ( ) : - Patient 's assessment overall pain VAS prior treatment - Patient 's global assessment disease activity VAS prior treatment</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Male female age 18 year The patient rheumatoid arthritis , define American Rheumatism Association . Assessment overall pain ( patient ) , washout NSAID least 2 day ( 3 day oxicams ) , must exceed 40 mm 100 mm visual analogue scale ( VAS ) Symptoms RA require administration NSAIDs Outpatients Willingness ability provide write informed consent . Known suspected hypersensitivity trial drug excipients , analgesic , antipyretic NSAIDs Any clinical evidence active peptic ulceration previous 6 month Pregnancy breastfeeding ( precaution : attention drawn report NSAIDs report decrease effectivity intrauterine device ) Asthma , nasal polyp , angioneurotic oedema urticaria follow administration aspirin NSAIDs Concomitant treatment anticoagulant ( include heparin ) , lithium Concomitant administration NSAIDs analgesic agent ( except paracetamol 4g/day ) Administration NSAID last 2 day ( 3 day oxicam ) prior first administration trial drug Concomitant treatment methotrexate , sulfasalazine , Dpenicillamine , chloroquine disease modify antirheumatic drug initiate alter dose previous 3 month Concomitant treatment oral corticosteroid initiate alter dose previous month Parenteral intraarticular administration corticosteroid previous month Any i.m . injection previous 7 day Synovectomy and/or surgical treatment RA previous month trial Any physiotherapy change trial Any contraindication i.m . injection Clinical evidence know severe cardiac , hepatic , renal , metabolic , haematological disease , mental disturbance , ulcerative colitis Any rheumatological nonrheumatological disease could interfere evaluation efficacy safety Serum creatinine 125 % upper limit normal range ; aspartate aminotransferase ( AST/SGOT ) and/or alaline aminotransferase ( ALT/SGPT ) 200 % upper limit normal range Platelet count &lt; 100,000/mm3 ; leucocyte count &lt; 3,000/mm3 Participation another clinical trial study previous month Previous participation trial ( i.e . allocate randomized treatment number ) Patient unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>